Phibro Reports First Full-Year Results After Medicated Feed Deal
Phibro Animal Health reported fiscal 2026 net sales above $1.5 billion, with adjusted EBITDA up 39% to $255 million and adjusted diluted EPS rising 48% to $3.22. The medicated feed additive portfolio helped: acquired business sales grew 70% and added $354.3 million. Animal Health and Mineral Nutrition also grew, but free cash flow fell to $9.9 million due to an $86.3 million inventory build and higher leverage.